LONDON, Sept 16- Roche's decision to buy U.S. biotech company InterMune for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions, the Swiss drugmaker's chief executive said on Tuesday.
NEW YORK, June 26- U.S. healthcare companies are winning higher profit forecasts, bucking a wider trend on Wall Street, as pricey new biotech drugs hit the market and insurance enrollment rises under the Affordable Care Act.
June 2- Alexion Pharmaceuticals Inc said it is voluntarily recalling certain lots of Soliris, an intravenous drug for two potentially fatal blood disorders that can damage the kidneys, heart and brain. The company said the recall was related to its earlier manufacturing process, which had prompted a similar recall in November.
*Hewlett-Packard's revenue misses Wall St estimates. Among momentum names, noted for high growth and perceptions of excessive valuation, Vertex Pharmaceuticals shares shot up 6 percent to $71.18, while Alexion Pharmaceuticals rose 2.5 percent to $160.48.
This quarter's earnings have a clear trend: they either beat expectations or report in-line, which does little to help the stock.
*Raises 2014 adj earnings forecast to $4.75- $4.85/ share. *1st- quarter adj earnings $1.53/ share vs est $1.26. The biotechnology company raised its full-year adjusted earnings forecast to $4.75- $4.85 per share from $4.37- $4.47.
April 24- Alexion Pharmaceuticals Inc reported stronger-than-expected adjusted net earnings due to robust sales of its sole product on the market, Soliris, and it raised its full-year profit forecast for the second time in less than two months.
NEW YORK, April 15- U.S. stocks fell on Tuesday as early gains evaporated when momentum shares once again lost ground, overshadowing a jump in Coca-Cola and Johnson& Johnson after their quarterly earnings. Tesla Motors Inc fell 5.5 percent to $187.25 and NetFlix Inc dropped 4.5 percent to $316.82 to rank among the worst performers in the Nasdaq 100 index.
This ETF has been the tip of the arrow when it comes to trading momentum stocks.
Some of Wednesday's midday movers:
April 8- The last six weeks have been rough for investors who jumped into 2013' s big stock market winners like Netflix and Facebook, only to see their share prices crater. For now, they have shifted money to other parts of the equities market, instead of retreating to safe-havens like cash, and concerns that there will be a full-scale retreat are muted.
The tumble of once highflying tech stocks signals a potential shift in investors chasing eye-popping growth, the New York Times reports.
On a terrible day for the Nasdaq 100, a third of its decline can be pegged on three much-loved stocks.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
Some of Tuesday's midday movers:
There is worry that the recent decline in copper and China's economic woes might be the start of a wider correction.
Some of Monday's midday movers:
Some of the names on the move ahead of the open.
Talk about following the money. Investors looking to beat the S&P 500 need only track companies that are spending the most money lobbying Washington.
Some of Thursday's midday movers: